On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...
The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...
CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and ...
Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Ovarian Cancer.
Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Kidney Cancer (Renal Cell Cancer).
Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...
rohit sharma ki wife Everest Medicines' Phase 3 Clinical Trial Application for Sacituzumab Govitecan Approved Pharmaceutical and Health Industry Weekly Report (September 23-September 27) [Two Sessions ...
INR:5297. bet365 founded The latest clinical progress of CRISPR/Cas9 gene editing therapy Everest Medicines' Phase 3 Clinical Trial Application for Sacituzumab Gov ...
The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...
Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data ...